ArticlePsychiatry investigation2021
Using Prazosin to Treat Posttraumatic Stress Disorder and Associations: A Systematic Review.
Article in Psychiatry investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Psychotherapeutic, pharmacological and other active interventions from the NICE guideline for post-traumatic stress disorder with sleep disorder: systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis.Annals of medicine · 2024Pooled it
- Memory reconsolidation impairment using the β-adrenergic receptor blocker propranolol reduces nightmare severity in patients with posttraumatic stress disorder: a preliminary study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Trial
- Glymphatic function restored by α1-noradrenergic antagonism alleviates headache allodynia in mice.bioRxiv : the preprint server for biology · 2026Article
- Comic: explainable drug repurposing via contrastive masking for interpretable connections.BMC bioinformatics · 2026Article
- Biomarkers and Mechanisms of Cardiovascular Susceptibility and Resilience to Post-Traumatic Stress Disorder.Reviews in cardiovascular medicine · 2025Review
- Post-Traumatic Stress and Stressor-Related Disorders in Hematological Malignancies: A Review.Journal of clinical medicine · 2025Review
- Shared genetic architecture of posttraumatic stress disorder with cardiovascular imaging, risk, and diagnoses.Nature communications · 2025Article
- Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: aFrontiers in psychiatry · 2025Article
- Genetics of posttraumatic stress disorder and cardiovascular conditions using Life's Essential 8, Electronic Health Records, and Heart Imaging.medRxiv : the preprint server for health sciences · 2024Article
- Review
- Article
- Doxazosin Immediate Release as a Novel Treatment for Nightmares in Posttraumatic Stress Disorder.Case reports in psychiatry · 2024Article
- Structural basis of αNature communications · 2023Article
- Stress circuitry: mechanisms behind nervous and immune system communication that influence behavior.Frontiers in psychiatry · 2023Review
- Case report: Prazosin augmentation for treating comorbid treatment-resistant depression and chronic post-traumatic stress disorder.Frontiers in psychiatry · 2022Article
- Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.Innovations in clinical neuroscienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA central adrenergic hyperactivation is described in the neurobiology of posttraumatic stress disorder (PTSD) with probable variable symptomatic impact. Few studies have evaluated using the alpha-1 adrenergic antagonist prazosin for such symptoms; however, given the likely pathophysiology involved, this drug may play an important role in the pharmacological approach to PTSD.
methodsThis study assessed articles already published on the use of prazosin through a systematic review along a timeline in view of the symptomatic target of difficult access by standardized treatments. The impact of using this medication for the general symptoms of PTSD is also discussed. Several databases were searched for articles in the literature on the use of prazosin to treat PTSD.
resultsA total of 168 articles were found containing search terms in the title or abstract. Overall, 85 articles met the criteria described, and 48 studies were explored to conduct the present systematic review. Most articles showed some improvement after prazosin administration, especially in relation to sleep symptoms (nightmares and night waking). Only one article demonstrated no improvement after the use of this drug. More randomized studies are needed.
conclusionSeveral clinical studies demonstrated the relevant role of prazosin for treating PTSD symptoms. Prazosin is an affordable and cost-effective pharmacological option compared to other drugs used to treat PTSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.